Wei-Ting Hwang, Ph.D.

Dr. Hwang’s methodological research interests include statistical methods for survival and longitudinal data, multistate processes, early-phase cancer trial design, and biomarker discovery and evaluation. Her primary collaborative research has focused on cancer, ranging from the basic science of tumor biology to clinical and translational research on patient outcomes. Additionally, she also collaborates in areas of psychosocial, environmental health, and diversity research. Currently she is serving as the director for Biostatistics and Data management Core for immuno/immuno-Gene Therapies for Thoracic Malignancies P01 and as the director of the Biostatistics Research Support Core for Penn's P42 Superfund Research (SRP) Center that studies mechanisms of asbestos remediation and asbestos-related diseases as well as the social impacts of asbestos exposures in the nearby Ambler, PA, community. In addition, she has been the principal statistician for Penn's cellular immunotherapy program since 2008 and has participated in clinical trial protocols that covered several disease indications, many of them are related to Chimeric Antigen Receptor (CAR) T-Cell Therapy. She is also a long-term member of Penn's Abramson Cancer Center (ACC) clinical trials scientific review and monitoring committee, and a member of the ACC Biostatistics Core. Previously she served as a co-director of the Biostatistics Core for an FCCC/Penn Ovarian SPORE (2010-2015) and participated in Skin SPORE and Melanoma target therapy P01 (2007-2010). She is a standing member for the NIH Clinical Oncology (CONC) study section and is on the editorial board for the journal of Health Psychology. She also serves as grant reviewer of several NIH and VA study sections, PCORI, as well as on two Data Safety Monitoring Boards/Committees.

Selected Publications

  • Rogers AE, Hwang W-T, Scott LD, Aiken LH, Dinges DF: The working hours of hospital staff nurses and patient safety. Health Affairs 23(4): 202-212, 2004.
  • Harris EE, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, Solin LJ: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. Journal of Clinical Oncology 24(25): 4100-4106, 2006.
  • Solin LJ, Orel SG, Hwang W-T, Harris EE, Schnall MD: Relationship of breast magnetic resonance imaging to outcome after breast- conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. Journal of Clinical Oncology 26(3): 386-391, 2008.
  • Alderfer MA, Mougianis I, Barakat LP, Beele D, DiTaranto S, Hwang W-T, Reilly AT, Kazak AE: Family psychosocial risk, distress and service utilization in pediatric cancer: predictive validity of the psychosocial assessment tool (PAT). Cancer 115(18): 4339-4349, Sep 2009.
  • Daymont C, Hwang W-T, Feudtner C, Rubin D. Distribution of head circumference measurements in a large U.S. primary care network differs substantially from CDC and WHO curves. Pediatrics 126(4):e836-842, 2010.
  • Hill-Kayser CE, Chacko D, Hwang W-T, Vapiwala N, Solin LJ: Long-term clinical and cosmetic outcomes after breast conservation treatment for women with early-stage breast carcinoma according to the type of breast boost. International Journal of Radiation Oncology Biology Physics 79(4): 1048-1054, Mar 2011.
  • Hwang W-T*, Adams SF*, Tahirovic E, Hagemann IS, Coukos G: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic Oncology. *Equal Contribution. 124(2): 192-198, Feb 2012.
  • Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine 4(132): 132ra53, May 2012
  • Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang W-T, Vaughn DJ, Malkowicz SB, Christodouleas JP: A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. International Journal of Radiation Oncology Biology Physics 85(1): 81-8, Jan 2013.
  • Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang W-T, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH: Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121(9): 1524-33, Feb 2013.
  • Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang W-T, Levine BL, June CH: Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. New England Journal of Medicine 370(10): 901-10, Mar 2014.
  • Christodouleas JP, Baumann BC, He J, Hwang W-T, Tucker KN, Bekelman JE, Tangen CM, Lerner SP, Guzzo TJ, Malkowicz SB: Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer 120(8): 1272-80, Apr 2014.
  • Zhong Q, Peng HL, Zhao X, Zhang L*, Hwang W-T*: Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clinical Cancer Research. *Corresponding authors, 21(1): 211-20, Jan 2015.
  • Vaughn DJ, Hwang W-T, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ: Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer 121(9): 1463-8, May 2015.
  • Garfall AL*, Maus MV*, Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine. *: Equal Contribution, 373(11): 1040-7, Sep 2015.
  • Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone M, Levine BL, Melenhorst JJ, June CH: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303): 303ra139, Sep 2015.
  • Baumann BC, He J, Hwang W-T, Tucker KN, Bekelman JE, Herr HW, Lernerm SP, Guzzo TJ, Malkowicz SB, Christodouleas JP: Validating a local failure risk stratification for use in prospective studies of adjuvant radiation therapy for bladder cancer. International Journal Radiation Oncology Biology Physics 95(2): 703-6, Jun 2016.
  • Ojerholm E, Smith A, Hwang W-T, Baumann BC, Tucker KN, Lerner SP, Mamtani R, Boursi B, Christodouleas JP: Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer Oct 2016.
  • Vapiwala N, Hwang W-T, Kushner C, Schnall, MD, Freedman GM, Solin LJ: No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer Dec 2016.